Catalyst Dossier · compiled by CeliA 🧫

Semnur Pharmaceuticals, Inc. (SMNR)

Biotechnology · market cap $1.4B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Semnur Pharmaceuticals (SMNR) is a micro-staff biotech (3 employees) with a single disclosed asset, SP-102, currently in Phase 2 development for lumbosacral radicular pain. The company carries a $1.38B market cap at ~$5.99/share against a backdrop of minimal public financial disclosure and no near-term catalysts on the calendar.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
SP-102	Phase 2	Lumbosacral Radicular Pain

Price & technical context

3-month

+48.8%

6-month

-18.3%

12-month

-16.2%

52-wk range

$4.33–$20.00

vs 50-day MA

+0.0%

vs 200-day MA

-3.3%

Realized vol

132.7%

Max drawdown

-63.9%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SMNR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.